Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MITCHELL B BERNSEN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1275523631
CMS profile
284632
Location
ARLINGTON HEIGHTS, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,080.81

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,889.48 74
Travel and Lodging $1,191.33 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MITCHELL B BERNSEN

NPI 1275523631 · CMS profile ID 284632

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ARLINGTON HEIGHTS, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275523631?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MITCHELL B BERNSEN, NPI 1275523631, CMS profile ID 284632. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275523631?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MITCHELL B BERNSEN, NPI 1275523631, CMS profile ID 284632. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275523631?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MITCHELL B BERNSEN, NPI 1275523631, CMS profile ID 284632, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1275523631?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $3,080.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $20.9106/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593961 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.3206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593963 CMS
Celgene Corporation $22.9706/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932585311 CMS
Janssen Biotech, Inc. $22.1505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885846505 CMS
ABBVIE INC. $18.8605/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890601671 CMS
ABBVIE INC. $15.7705/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890601669 CMS
Gilead Sciences, Inc. $17.9305/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929550571 CMS
Medtronic, Inc. $17.0605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930631451 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.6705/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593959 CMS
Amgen Inc. $22.0505/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939369865 CMS
ABBVIE INC. $14.3905/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890601667 CMS
Gilead Sciences, Inc. $21.2004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929550579 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.2004/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593957 CMS
Janssen Biotech, Inc. $15.9403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885846481 CMS
Janssen Biotech, Inc. $19.1503/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885846469 CMS
Janssen Biotech, Inc. $7.4803/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885846475 CMS
ABBVIE INC. $15.6803/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890601665 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.5203/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593955 CMS
Janssen Biotech, Inc. $4.7402/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885846465 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.6102/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593951 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.2002/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955593953 CMS
ABBVIE INC. $17.8902/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890601663 CMS
Ironwood Pharmaceuticals, Inc $14.7201/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957911509 CMS
Janssen Biotech, Inc. $4.9001/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885846485 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.5501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960030681 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,276.39 97
PY2020 $386.09 22
PY2021 $3,650.80 57
PY2022 $3,080.81 75
PY2023 $2,628.31 123
PY2024 $2,877.67 116
PY2025 $3,201.36 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $17,455.47 27
PY2024 Principal investigator $980.45 2
PY2023 Principal investigator $73,392.06 15
PY2022 Principal investigator $16,377.67 6
PY2021 Principal investigator $31,795.00 7
PY2020 Principal investigator $37,146.96 10
PY2019 Principal investigator $25,855.15 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289610
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289612
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289634
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289636
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289648
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289392
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289394
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289396
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 12/10/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289464
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283793
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283795
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283799
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283801
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283805
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283811
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 07/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223282274
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 07/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223282276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 01/08/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223273731
Principal investigator 1 ABBVIE INC. $80.97 01/03/2025 Non-covered Recipient Entity
ILLINOIS GASTROENTEROLOGY GROUP LLC
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202436527

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $29,005.82 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $29,005.82 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $1,821.89 1
PY2021 Amount invested $1,223.42 1
PY2021 Value of interest $1,529.69 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $29,005.82 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124818311
PY2023 GastroGPO, LLC $0.00 $29,005.82 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050729649
PY2022 GastroGPO, LLC $0.00 $1,821.89 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 954999641
PY2021 GastroGPO, LLC $1,223.42 $1,529.69 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854914283